BIP! Finder for COVID-19

This version of BIP! Finder aims to ease the exploration of COVID-19-related literature by enabling ranking articles based on various impact metrics.

Last Update: 28 - 02 - 2021

Provided impact measures:
Popularity: Citation-based measure reflecting the current impact.
Influence: Citation-based measure reflecting the total impact.
Reader Attention: The current number of Mendeley readers.
Social Media Attention: The number of tweets related to this article.
*More details on these impact measures can be found here.
Score interpretations:
Exceptional score (in top 0.01%).
Substantial score (in top 1%).
Average score (in bottom 99%).
Score not available.
Main data sources:
CORD-19 dataset(1) (list of papers)
LitCovid hub(2) (list of papers)
PMC & PubMed (citations)
Mendeley (number of readers)
COVID-19-TweetIDs(3) (tweets)
1Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trialTrials2020       LitCov and CORD-19
2Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet2020       LitCov and CORD-19
3Antibody tests for identification of current and past infection with SARS-CoV-2Cochrane Database Syst Rev2020       LitCov and CORD-19
4Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trialTrials2020       LitCov and CORD-19
5The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trialTrials2020       LitCov and CORD-19
6Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyLancet2020       LitCov and CORD-19
7Clinical Characteristics of COVID-19 in ChinaN Engl J Med2020       LitCov and CORD-19
8Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-center studyJ Med Microbiol2020       LitCov and CORD-19
9Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, ChinaJAMA2020       LitCov and CORD-19
10A Novel Coronavirus from Patients with Pneumonia in China, 2019N Engl J Med2020       LitCov and CORD-19
11Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyLancet2020       LitCov and CORD-19
12Interventions to support the resilience and mental health of frontline health and social care professionals during and after a disease outbreak, epidemic or pandemic: a mixed methods systematic reviewCochrane Database Syst Rev2020       LitCov and CORD-19
13PROTECT Trial: A cluster-randomized study with hydroxychloroquine vs observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trialTrials2020       LitCov and CORD-19
14Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent SARS-CoV-2 infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trialTrials2020       LitCov and CORD-19
15Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trialTrials2020       LitCov and CORD-19
16A pneumonia outbreak associated with a new coronavirus of probable bat originNature2020       LitCov and CORD-19
17Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir Med2020       LitCov and CORD-19
18Characteristics of and Important Lessons From the COVID-19 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and PreventionJAMA2020       LitCov and CORD-19
19Human and novel coronavirus infections in children: a reviewPaediatr Int Child Health2020       LitCov and CORD-19
20The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the statusMil Med Res2020       LitCov and CORD-19
21Physical interventions to interrupt or reduce the spread of respiratory virusesCochrane Database Syst Rev2020       LitCov and CORD-19
22Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected PneumoniaN Engl J Med2020       LitCov and CORD-19
23Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?Biomolecules2020       LitCov and CORD-19
24SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell2020       LitCov and CORD-19
25Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trialTrials2020       LitCov and CORD-19
26Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, ItalyJAMA2020       LitCov and CORD-19
27COVID-19: a conundrum to decipherEur Rev Med Pharmacol Sci2020       LitCov and CORD-19
28Quarantine alone or in combination with other public health measures to control COVID-19: a rapid reviewCochrane Database Syst Rev2020       LitCov and CORD-19
29Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingLancet2020       LitCov and CORD-19
30Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infectionCochrane Database Syst Rev2020       LitCov and CORD-19
31A Practical Approach to the Management of Cancer Patients During the Novel COVID-19 (COVID-19) Pandemic: An International Collaborative GroupOncologist2020       LitCov and CORD-19
32A hundred days into the coronavirus disease (COVID-19) pandemicEuro Surveill2020       LitCov and CORD-19
33[Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?]Encephale2020       LitCov and CORD-19
34The novel zoonotic COVID-19 pandemic: An expected global health concernJ Infect Dev Ctries2020       LitCov and CORD-19
35Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemicActa Biomed2020       LitCov and CORD-19
36Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote AustraliaMed J Aust2020       CORD-19
37Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic reviewUltrasound Obstet Gynecol2020       LitCov and CORD-19
38Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping reviewCochrane Database Syst Rev2020       LitCov and CORD-19
39Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyLancet Infect Dis2020       LitCov and CORD-19
40Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)J Pathol2020       LitCov and CORD-19
41A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study pTrials2020       LitCov and CORD-19
42Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid reviewCochrane Database Syst Rev2020       LitCov and CORD-19
43Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspectiveJ Allergy Clin Immunol2020       LitCov and CORD-19
44Norwegian COVID-19 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trialTrials2020       LitCov and CORD-19
45A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family clusterLancet2020       LitCov and CORD-19
46Antiviral Activity of Type I, II and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2mBio2020       LitCov and CORD-19
47Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care center in New DelhiJ Assoc Physicians India2020       LitCov and CORD-19
48Randomised controlled trial comparing efficacy and safety of high vs low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocolTrials2020       LitCov and CORD-19
49Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, ChinaBMC Pregnancy Childbirth2020       LitCov and CORD-19
50Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling studyPLoS Med2020       LitCov and CORD-19

(1) COVID-19 Open Research Dataset (CORD-19). 2020. Version 2021-2-08. Retrieved from Accessed 2021-02-14. doi:10.5281/zenodo.3715506
(2) Chen Q, Allot A, & Lu Z. (2020) Keep up with the latest coronavirus research, Nature 579:193 and Chen Q, Allot A, Lu Z. LitCovid: an open database of COVID-19 literature. Nucleic Acids Research. 2020. (version 2021-02-14)
(3) Currently tweets of November 21 to November 27, 2020 have been considered.

This service is provided "as is", without any warranties of any kind.